I thought bisantrene concentration and FTO inhibition, just like with cardioprotection, is not linearly related and is dose-dependent. One big thing with bisantrene is synergy synergy synergy. It makes other drugs work better, at no added cost to the patient. So in Sheba 2, it is possible the response rates are not related to FTO etc but due to the other 2 combo drugs. We won't know until more data is released, but it's a win-win. Either it's FTO, or it's still bisantrene, but by amplifying the impact of the other drugs. Just my thoughts
RAC Price at posting:
97.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)